Regorafenib (BAY 73-4506)

Catalog No.S1178 Synonyms: Fluoro-Sorafenib

Regorafenib (BAY 73-4506) Chemical Structure

Molecular Weight(MW): 482.82

Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 168 In stock
USD 120 In stock
USD 210 In stock
USD 470 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective VEGFR Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Regorafenib (BAY 73-4506) is a multi-target inhibitor for VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM, 22 nM, 7 nM, 1.5 nM and 2.5 nM in cell-free assays, respectively.
Targets
RET [1]
(Cell-free assay)
Raf-1 [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
Kit [1]
(Cell-free assay)
VEGFR1 [1]
(Cell-free assay)
1.5 nM 2.5 nM 4.2 nM 7 nM 13 nM
In vitro

Regorafenib strongly prevents VEGFR2 autophosphorylation in NIH-3T3/VEGFR2 cells with IC50 of 3 nM. In HAoSMCs, regorafenib suppress PDGFR-β autophosphorylation after stimulation with PDGF-BB, with an IC50 of 90 nM. Regorafenib also inhibits FGFR signaling in MCF-7 breast cancer (BC) cells stimulated with FGF10. Regorafenib very potently inhibited the mutant receptors KITK642E and RETC634W, with IC50 of approximately 20 nM and 10 nM, respectively. Regorafenib inhibits the proliferation of VEGF165-stimulated HUVECs, with an IC50 of approximately 3 nM. Regorafenib prevents the proliferation of FGF2-stimulated HUVECs and of PDGF-BB-stimulated HAoSMCs with IC50 of 127 nM and 146 nM, respectively. [1] Regorafenib targets both tumor cell proliferation and tumor vasculature through inhibition of receptors of tyrosine kinases (VEGFR, KIT, RET, FGFR, and PDGFR) and serine/threonine kinases (Raf and p38MAPK). [2] Regorafenib suppresses growth of human Hep3B, PLC/PRF/5 and HepG2 cells in a concentration- and time-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B MnHjRZBweHSxc3nzJGF{e2G7 NHTibWUy6oDVNdMg{txO NX3reWs5PDhiaB?= MUTpcohq[mm2czDj[YxtKGe{b4f0bC=> MWWyOlMzQTZyOB?=
PLC/PRF/5  NIDk[oxCeG:ydH;zbZMhSXO|YYm= MYKx5qCUPcLizszN MoTxOFghcA>? Mo\MbY5pcWKrdIOgZ4VtdCCpcn;3eIg> NWLKbngzOjZ|Mkm2NFg>
HepG2  M3P1dWFxd3C2b4Ppd{BCe3OjeR?= NUPufmlvOeLCk{ZCpO69VQ>? NXK1dm9EPDhiaB?= Mo[4bY5pcWKrdIOgZ4VtdCCpcn;3eIg> MlLYNlY{Ojl4MEi=
HEK293 MnTkSpVv[3Srb36gRZN{[Xl? NYrPOpBVOC534pEJ{txO MmPNNk81NzZiaB?= MWPy[YR2[2W|IFfSVFc5KGW6cILld5Nqd25? MXSyOVg2QDB|Mh?=
GEO M4HSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHoXIhxOC5yMT2yNEDPxE1? M4HRbVk3KGh? MWLEUXNQ MXnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NETqUpUzPTh|OEO5NS=>
SW48 M1TMNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\zNE4xOS1{MDFOwG0> NHjQTGc6PiCq NET6RmpFVVOR Mm[wbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NH3VZ5kzPTh|OEO5NS=>
HT29 M2C1NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzrb|ROOC5yMT2yNEDPxE1? NFLQXFQ6PiCq M1\HcmROW09? M1\OdIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NV7xTZJEOjV6M{izPVE>
SW480 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rjWVAvODFvMkCg{txO NH3ldmw6PiCq MUPEUXNQ MorPbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWqyOVg{QDN7MR?=
SW620 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPPNE4xOS1{MDFOwG0> MnHNPVYhcA>? MkG3SG1UVw>? NFrxXI9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NWLBT5Z6OjV6M{izPVE>
HCT116 NVvKOWJET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnP6NE4xOS1{MDFOwG0> M2fEWFk3KGh? NUD0[|MzTE2VTx?= M1jCTYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHPGbWYzPTh|OEO5NS=>
LOVO NFr4b4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn4V25DOC5yMT2yNEDPxE1? NF7D[Y86PiCq NXLTNpRoTE2VTx?= NILwR4VqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M{DTTlI2QDN6M{mx
HCT150 MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L2cVAvODFvMkCg{txO NXnRfXNIQTZiaB?= MkS5SG1UVw>? MYrpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mm\SNlU5Ozh|OUG=
SW48-CR NUHXR5lwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi1NE4xOS1{MDFOwG0> M3nLNFk3KGh? MoXHSG1UVw>? NXzJb|BpcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFrDVZAzPTh|OEO5NS=>
GEO-CR NVfjU5Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnqNJNqOC5yMT2yNEDPxE1? NGSzTIc6PiCq MmHUSG1UVw>? M4mxNIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MkTINlU5Ozh|OUG=
KB-31 M37le2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrXVlNKSzVyPUWuOeKyOC5|IH7N NUDzb3hJOjV5NUOzOlE>
KB-G2 MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXjTWM2OD17LkJCtVAvOSCwTR?= M2TGcFI2PzV|M{[x
LLC-PK1 MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17p[GlEPTB;NEKuNOKyOy5{IH7N NInWVYUzPTd3M{O2NS=>
LLC-PK1/MRP2 NFLLeXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3mWmdKSzVyPUiyMlTDuTJwNzDuUS=> NILhT5QzPTd3M{O2NS=>
HEK293 NWDkR41{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFzLkFCtVEvOiCwTR?= NUWxNnZxOjV5NUOzOlE>
HEK293/OATP1B1 MkXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;rOJlKSzVyPU[uNuKyOC5|IH7N NHfkcGYzPTd3M{O2NS=>
HROC18 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS0fnFKSzVyPUGuN{DPxE1? MVWyOVMxQTlzNB?=
HROC24 NH\OXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjPXWpqUUN3ME20MlYh|ryP NULXU2JFOjV|MEm5NVQ>
HROC43 M1HWcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TXTWlEPTB;NT6zJO69VQ>? NWnJRZFOOjV|MEm5NVQ>
HROC46 NG\mSlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG3TWM2OD1{LkSg{txO M3XUPVI2OzB7OUG0
RJ345 NVHkbJp5TnWwY4Tpc44hSXO|YYm= M3vCRVAvPS93IN88US=> MkTzNlQhcA>? NIO1VWVFVVOR MoezbY5pcWKrdIOgeIhmKGOnbHygcYloemG2aX;u M2fLRlI2OjV|OUm0
RJ348 NXzDOIV7TnWwY4Tpc44hSXO|YYm= MVSwMlUwPSEQvF2= NGXOUGczPCCq M1zpSmROW09? NGHXT2RqdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> NW\OSm9DOjV{NUO5PVQ>
MCF-7 NFXVTm9HfW6ldHnvckBCe3OjeR?= NWLsfVB4OC53L{Wg{txO MX2yOEBp M3fNWmROW09? MorFbY5pcWKrdIOgeIhmKGOnbHygcYloemG2aX;u MkjZNlUzPTN7OUS=
MDA-MB-231 MXTGeY5kfGmxbjDBd5NigQ>? MofYNE42NzVizszN NFK1WGwzPCCq NGLGOZVFVVOR NGj2cIRqdmirYnn0d{B1cGViY3XscEBucWe{YYTpc44> MWSyOVI2Ozl7NB?=
HT15 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13L[lEuOjBizszN NIf3[Zg1QCCq MnXnbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUX0cmdpOjVyN{GwNVg>
DLD1 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PDZlEuOjBizszN MX20PEBp NELobJVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NYjTPJlYOjVyN{GwNVg>
HT-29 NFz4UGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVmxMVIxKM7:TR?= MkPCOFghcA>? NVzZb2U3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MofLNlUxPzFyMUi=
Hct-116 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfKeYoyNTJyIN88US=> M2K5fFQ5KGh? NGnLPYRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MVOyOVA4OTBzOB?=
HT15 MYTBdI9xfG:|aYOgRZN{[Xl? M4nxSVEuOTBizszN MXy0PEBp NWnKWWNHcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Ml7pNlUxPzFyMUi=
DLD1 NUHXS4sySXCxcITvd4l{KEG|c3H5 NV3rbnBkOS1zMDFOwG0> MmLOOFghcA>? M1m1Nolv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> Mn32NlUxPzFyMUi=
HT-29 MlTyRZBweHSxc3nzJGF{e2G7 M2\wVVEuOTBizszN NGDvUZI1QCCq M1PSW4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MXyyOVA4OTBzOB?=
Hct-116 MWDBdI9xfG:|aYOgRZN{[Xl? NUTlPVdyOS1zMDFOwG0> NFfKc|U1QCCq M4DiPIlv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NWG3fYRMOjVyN{GwNVg>
GBM5 NILaRWVCeG:ydH;zbZMhSXO|YYm= MmTMNE426oDVMT6w5qCK|ryP M2exNVI1KGh? MVPEUXNQ NWnvXIRVcW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp Mmi0NlQ6OTF{MUW=
GBM6 NIrNTYlCeG:ydH;zbZMhSXO|YYm= Mk[xNE426oDVMT6w5qCK|ryP NFn3PZUzPCCq MkjjSG1UVw>? M{O3UYlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> NXP1UnlTOjR7MUGyNVU>
GBM12 NY\WTmNRSXCxcITvd4l{KEG|c3H5 Mo\INE426oDVMT6w5qCK|ryP M4\QcFI1KGh? NF7XXm5FVVOR M4X6bYlvfGW{YXP0d{B4cXSqIHzhdIF1cW6rYjD0c{BqdmS3Y3WgZ4VtdCCmZXH0bC=> M1POT|I1QTFzMkG1
GBM14  M4LNdGFxd3C2b4Ppd{BCe3OjeR?= M{nnWVAvPeLCk{GuNQKBkc7:TR?= NWPpeY5UOjRiaB?= NGPGSXdFVVOR NYTMSGxVcW62ZYLhZ5R{KHerdHigcIFx[XSrbnniJJRwKGmwZIXj[UBk\WyuIHTlZZRp NXGzbY04OjR7MUGyNVU>
Hep3B NXfLbIZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEftPVky6oDVMj61xsDPxE1? MWWyOE81QC95MjDo Mni5bY5pcWKrdIOgZ4VtdCCpcn;3eIg> M1XPOVI1QDh3OEmw
PLC/PRF/5  M2jYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPBR4Uy6oDVMj61xsDPxE1? NEP6WXczPC92OD:3NkBp MmSybY5pcWKrdIOgZ4VtdCCpcn;3eIg> NFnqW3UzPDh6NUi5NC=>
HepG2  M1excWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXyx5qCUOi53wrFOwG0> NIPUR40zPC92OD:3NkBp M33hNIlvcGmkaYTzJINmdGxiZ4Lve5Rp NU\Qe41NOjR6OEW4PVA>
HCT116  NI\wZVBHfW6ldHnvckBCe3OjeR?= MW[xNE8zOC92MDFOwG0> NFvIZ2IzPCCq NWrOSoJKcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJI1TVkFiZYjwdoV{e2mxbjDpckBiKGSxc3WtJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= MnHjNlQ4PjN4MUG=
Lim2405 M{H5TGZ2dmO2aX;uJGF{e2G7 M1Lhd|QxKM7:TR?= M33ldlI1KGh? Mlv2bY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ M1zve|I1PzZ|NkGx
LoVo M2e0OGZ2dmO2aX;uJGF{e2G7 MUC0NEDPxE1? NHfiRVYzPCCq NETJNZhqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? M4jIclI1PzZ|NkGx
Lim1215 M{TSPGZ2dmO2aX;uJGF{e2G7 MkfVOFAh|ryP NGC0c48zPCCq M3nPeIlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? NYHHNVluOjR5NkO2NVE>
SW48 MYfGeY5kfGmxbjDBd5NigQ>? NVHSV|ViPDBizszN NVuxTHZKOjRiaB?= NXraNWFEcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| MVWyOFc3OzZzMR?=
RKO  M1TwSmZ2dmO2aX;uJGF{e2G7 MUm0NEDPxE1? NYi3Smo{OjRiaB?= NXf5OFNxcW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| MVOyOFc3OzZzMR?=
SW837 MkP0SpVv[3Srb36gRZN{[Xl? NEm3S4M1OCEQvF2= MkHkNlQhcA>? MUPpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> Mo\qNlQ4PjN4MUG=
SW1463 NF75Z3dHfW6ldHnvckBCe3OjeR?= MW[0NEDPxE1? MYWyOEBp M2eySYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? NFu4eXAzPDd4M{[xNS=>
SW480 NUXnXGZuTnWwY4Tpc44hSXO|YYm= MUS0NEDPxE1? MlHrNlQhcA>? MUfpcoR2[2W|IGDVUWEheHKxdHXpckBidmRiY3XscEBieG:ydH;zbZM> NWTXVGhDOjR5NkO2NVE>
Vaco432 MkPlSpVv[3Srb36gRZN{[Xl? MUO0NEDPxE1? MkX3NlQhcA>? NYTFWY1scW6mdXPld{BRXU2DIIDyc5RmcW5iYX7kJINmdGxiYYDvdJRwe2m| NES0cmczPDd4M{[xNS=>
Vaco400 M3zOWWZ2dmO2aX;uJGF{e2G7 M1qzSlQxKM7:TR?= MWCyOEBp M4XTcYlv\HWlZYOgVHVOSSCycn;0[YlvKGGwZDDj[YxtKGGyb4D0c5Nqew>? NIjNWnkzPDd4M{[xNS=>
DLD1 NV;odFRJTnWwY4Tpc44hSXO|YYm= M1;HSVQxKM7:TR?= MY[yOEBp NHXq[FJqdmS3Y3XzJHBWVUFicILveIVqdiCjbnSgZ4VtdCCjcH;weI9{cXN? NHL3RYwzPDd4M{[xNS=>
HT29  MV\GeY5kfGmxbjDBd5NigQ>? NXPBO48xPDBizszN MnPnNlQhcA>? Mk\tbY5lfWOnczDQWW1CKHC{b4TlbY4h[W6mIHPlcIwh[XCxcITvd4l{ M3ztS|I1PzZ|NkGx
PLC/PRF/5  NGXKd2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfl[JNIOeLCk{ZCuW0> Mnv1NlQwPDhxN{KgbC=> NVP1e217cW6qaXLpeJMh[2WubDDndo94fGh? MnvJNlMyPjlzNEi=
HepG2 M4rhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXwXVQy6oDVNdM1US=> M4XaNFI1NzR6L{eyJIg> M4rt[4lvcGmkaYTzJINmdGxiZ4Lve5Rp NGXPN4IzOzF4OUG0PC=>
Hep3B  NX7pTo9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKx5qCUPcL3TR?= M3;hNFI1NzR6L{eyJIg> NUi0fmhFcW6qaXLpeJMh[2WubDDndo94fGh? NX63ephYOjNzNkmxOFg>

... Click to View More Cell Line Experimental Data

In vivo Regorafenib reveals potent dose-dependent TGI in various preclinical human xenograft models in mice, with tumor shrinkages in breast MDA-MB-231 and renal 786-O carcinoma models. Regorafenib prevents not only the growth of syngeneic primary 4T1 breast tumors growing orthotopically in the fat pad, but also suppresses the formation of tumor metastasis in the lung. [1]

Protocol

Kinase Assay:[1]
+ Expand

Kinase assays:

In vitro assays using recombinant VEGFR2 (murine aa785–aa1367), VEGFR3 (murine aa818–aa1363), PDGFRβ (aa561–aa1106), Raf-1 (aa305–aa648) and BRafV600E (aa409–aa765) kinase domains are performed. Initial in vitro kinase inhibition profiling is performed at a fixed 1 μM Regorafenib concentration. Inhibitory concentration of 50% (IC50) values are determined from selected responding kinases, e.g., VEGFR1 and RET. TIE2 kinase inhibition is measured with a homogeneous time-resolved fluorescence (HTRF) assay using a recombinant fusion protein of glutathione-S-transferase, the intracellular domain of TIE2 and the peptide biotin-Ahx-EPKDDAYPLYSDFG as substrate.
Cell Research:[1]
+ Expand
  • Cell lines: GIST 882 and TT cells
  • Concentrations: 5 nM-10 μM
  • Incubation Time: 96 hours
  • Method: For proliferation assays, GIST 882 and TT cells are grown in RPMI medium containing L-glutamine, and MDA-MB-231, HepG2 and A375 cells in DMEM always containing 10% hiFBS. Cells are trypsinized, plated at 5×104 cells/well in 96-well plates in complete media containing 10% FBS and grown overnight at 37 °C. The next day, vehicle or Regorafenib serially diluted in complete growth media to between 10 μM and 5 nM final concentrations, and 0.2% DMSO, is added and incubation is continued for 96 hours. Cell proliferation is quantified.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female athymic NCr nu/nu mice with Colo-205, MDA-MB-231 or 786-O
  • Formulation: PEG400/125 mM aqueous methanesulfonic acid (80/20) or polypropylene glycol/PEG400/Pluronic F68 (42.5/42.5/15 + 20% Aqua)
  • Dosages: 3 mg/kg, 10 mg/kg, 30 mg/kg, 100 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 97 mg/mL (200.9 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol 30 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 482.82
Formula

C21H15ClF4N4O3

CAS No. 755037-03-7
Storage powder
in solvent
Synonyms Fluoro-Sorafenib

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02795156 Recruiting Non-small Cell Lung Carcinoma|Urothelial Carcinoma|Gastrointestinal Carcinoma, Non-colon|Upper Aerodigestive Tract Carcinoma SCRI Development Innovations, LLC|Foundation Medicine|Boehringer Ingelheim|Bayer September 28, 2016 Phase 2
NCT03042689 Not yet recruiting Acute Myeloid Leukemia Massachusetts General Hospital|Bayer January 2017 Phase 1
NCT02910843 Not yet recruiting Rectal Cancer Swiss Group for Clinical Cancer Research December 2016 Phase 1
NCT02940223 Not yet recruiting Malignant Neoplasms of Independent (Primary) Multiple Sites|Metastatic Colorectal Cancer M.D. Anderson Cancer Center|Bayer December 2016 Phase 2
NCT02955940 Enrolling by invitation Pancreatic Cancer|Colorectal Cancer|Breastcancer|Lung Cancer Non-Small Cell Incyte Corporation November 2016 Phase 2
NCT02889328 Recruiting Gastrointestinal Stromal Tumors (GISTs) Asan Medical Center September 2016 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

VEGFR Signaling Pathway Map

VEGFR Inhibitors with Unique Features

Related VEGFR Products

Tags: buy Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) supplier | purchase Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) cost | Regorafenib (BAY 73-4506) manufacturer | order Regorafenib (BAY 73-4506) | Regorafenib (BAY 73-4506) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID